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Gram-negative bacteria utilize heptoses as part of
their repertoire of extracellular polysaccharide viru-
lence determinants. Disruption of heptose biosyn-
thesis offers an attractive target for novel antimicro-
bials. A critical step in the synthesis of heptoses
is their 1-O phosphorylation, mediated by kinases
such as HldE orWcbL. Here, we present the structure
of WcbL from Burkholderia pseudomallei. We report
that WcbL operates through a sequential ordered Bi-
Bi mechanism, loading the heptose first and then
ATP. We show that dimeric WcbL binds ATP anti-
cooperatively in the absence of heptose, and coop-
eratively in its presence. Modeling of WcbL suggests
that heptose binding causes an elegant switch in the
hydrogen-bonding network, facilitating the binding
of a second ATP molecule. Finally, we screened a
library of drug-like fragments, identifying hits that
potently inhibit WcbL. Our results provide a novel
mechanism for control of substrate binding and
emphasize WcbL as an attractive anti-microbial
target for Gram-negative bacteria.
INTRODUCTION
Bacterial cells display a variety of polysaccharides and glyco-
conjugates in their cell walls and external structures. The func-
tions of thesemacromolecules includemaintaining the structural
integrity of the cell (e.g. peptidoglycan), defense against a
diverse range of environmental insults, and providing virulence
determinants for the invasion of hosts (Lovering et al., 2012; Mat-
suura, 2013; Whitfield, 2006). The polysaccharides of particular
relevance for infection are the lipopolysaccharides (LPS) and
capsular polysaccharides (CPS). The LPS core is required in
most bacteria for the structural integrity of the outer membrane
(Raetz andWhitfield, 2002), while LPS O antigens and CPS often
provide bacteria with protection in different or novel niches,
including the human body (Kingsley and Baumler, 2000; Whit-
field, 2006). These extracellular structures surrounding the mi-1622 Chemistry & Biology 22, 1622–1632, December 17, 2015 ª2015crobial cell consist of polymers of sugars that are often not found
in eukarya.
One important group of bacterial sugars are the heptoses
(Kosma, 2008). These are found in the LPS core ofmost common
bacteria (Figure 1A) and inmanyO antigens or CPS (e.g.Shigella,
Yersinia pseudotuberculosis, Campylobacter jejuni O antigen;
Burkholderia pseudomallei CPS-I [DeShazer et al., 2001; Paci-
nelli et al., 2002; Reckseidler et al., 2001]). Depending on the final
product that is required by the bacterium, these sugars are
biosynthesized from the ubiquitous pentose phosphate pathway
intermediate sedoheptulose-7-phosphate (S7P) by one of two
biological pathways (Butty et al., 2009). For a-heptopyranosides,
which generally occur in the LPS core, D-glycero-D-manno-
heptopyranose is synthesized from S7P as a b-configured ADP
conjugate in a four-step pathway. Two steps are catalyzed by
a bifunctional enzyme, HldE. b-D-manno-Heptopyranosides,
usually being present in O antigens or CPS, are similarly synthe-
sized as an a-guanosine diphosphate (GDP) conjugate via a
four-step pathway: two enzymes, GmhA and GmhB, are shared
between the two pathways, but HldE is replaced by two separate
enzymes. In some organisms, the GDP-heptopyranose is
then further processed to the 6-deoxy sugar (e.g. C. jejuni,
Y. pseudotuberculosis; Figure 1B) (Gilbert et al., 2007; Pacinelli
et al., 2002).
The biosynthetic pathways for heptoses have been proposed
as an excellent source of novel antibiotics (Durka et al., 2011;
Taylor and Wright, 2008): similar sugars are not found in mam-
mals, and the sugars are widely used by bacteria, so any inhibitor
would have a broad spectrum. Compounds active against the ki-
nase activity of HldE at micromolar concentrations have been
identified (De Leon et al., 2006; Lee et al., 2013). The develop-
ment of compounds targeting the GDP-linked biosynthetic path-
ways has not had the same attention, partly because the kinases
have not been as thoroughly characterized as HldE. These GDP-
linked pathways are usually used in O antigens and CPS, which
are usually required for infectivity, not viability. As such, antibi-
otics are likely to have lower selection pressure for resistance,
and fewer effects on the commensal flora.
The Gram-negative bacterium B. pseudomallei requires CPS
for full virulence (Atkins et al., 2002; Nelson et al., 2004; Vivoli
et al., 2014a). This pathogen is the causative agent of melioido-
sis, the most common cause of community-acquired septicemia
in many regions of South-East Asia (Stone, 2007; WiersingaThe Authors
Figure 1. Heptoses in Gram-Negative Bacteria
(A) Schematic representation of exopolysaccharide structures. Lipopolysac-
charide (LPS) forms the outer leaflet of the outer membrane of Gram-negative
bacteria, which comprises several regions: the lipid A portion composed of
two linked glucosamine residues (oblongs) with fatty acid side chains (curved
lines), an internal oligosaccharide bound to lipid A by 3-deoxy-D-manno-oct-
2-ulosonic acid (Kdo; blue hexagon). Heptose moieties (green hexagons; P,
phosphate groups) complete the inner core of LPS. Attached to the inner core
are various hexose sugars (violet hexagons), which form the outer core region.
The O chain is a repeating unit (n) of specific sugar residues (pink hexagons)
that forms the basis for serotyping, and is bound to the internal oligosaccha-
ride. The capsular polysaccharide (CPS), associated with the LPS, is an un-
branched homopolymer with the structure -3)-2-O-acetyl-6-deoxy-b-D-
manno-heptopyranose-(1-.
(B) Proposed biosynthetic pathway of CPS inBurkholderia pseudomallei. GDP,
guanosine diphosphate; GTP, guanosine triphosphate; PPi, pyrophosphate.et al., 2012). This organism is amajor clinical problem as it shows
intrinsic high-level resistance to many antibiotics, and relapse is
common even after long-term antibiotic treatment (Lazar Adler
et al., 2009). Mortality from septicemia ranges from 14% to
50%, depending on treatment, and up to 90% if untreated (Lim-
mathurotsakul and Peacock, 2011; White, 2003). The organism
is also considered to be a significant threat for bioterrorism
(Rotz et al., 2002) and is currently classed by the US Centers
for Disease Control and Prevention as a tier-1 agent (Butler,
2012); new treatments are being urgently sought by the USA
and UK defense agencies. In B. pseudomallei, CPS is bio-
synthesized by a cluster of 24 genes (DeShazer et al., 2001;
Holden et al., 2004; Reckseidler et al., 2001), whose function
has been proposed from bioinformatics and functional studies
(Cuccui et al., 2012). In the initial steps of CPS production,
GmhA transforms S7P into D-glycero-D-manno-heptose-7-
phosphate, which is further phosphorylated. It has been pro-
posed that the heptokinase activity is contributed byWcbL (Cuc-
cui et al., 2012). We therefore sought to determine the structure
and mechanism of the WcbL protein, and to understand how
amenable it might be to being inhibited by a novel compound.
Here, we describe the crystal structure of WcbL, solved to
1.78 A˚, together with separate complexes with the substrate
analogs AMP-PNP and D-mannose. The structure shows a
classical GHMP sugar kinase fold, and maintains some ofChemistry & Biothe conserved residues required for ATP binding and catalysis.
Combining the positions of AMP-PNP and mannose suggests
that these analogs occupy the likely positions of the true sub-
strates before catalysis commences. We demonstrate that mu-
tation of likely active-site residues ablates enzyme activity both
in vitro and in vivo, allowing us to propose a catalytic mecha-
nism. We show that WcbL modulates its cooperative behavior
for ATP depending on whether it has its sugar partner bound,
and that this is mediated through the global hydrogen-bonding
network. Finally, we show that specific inhibition of WcbL by
drug-like fragments can be achieved with high ligand effi-
ciency, indicating that the development of high-affinity, spe-
cific inhibitors of the GDP-linked heptose pathway should be
possible.
RESULTS
Overall Structure of WcbL
To improve our understanding of WcbL, we solved the crystal
structure of the enzyme to 1.78 A˚ resolution (Table S1). The
structure was solved using the single-wavelength anomalous
dispersion (SAD) method, using selenomethionine-labeled pro-
tein to provide a strong anomalous signal. WcbL crystals seem
to have lattice translocation disorder, as can be judged by
streaky reflections in certain directions. Crystals appear to
contain domains with the orthorhombic base-centered unit cell
and with a smaller monoclinic base-centered cell in which pseu-
dotranslation observed in the orthorhombic cell becomes crys-
tallographic. Native WcbL and an AMP-PNP complex had a
lower proportion of the monoclinic fraction: for these complexes
data did not process well and the model did not refine in the
monoclinic space group. The glycerol and mannose complex
crystals had a higher proportion of the monoclinic cell: these
data could be processed, and the models refined well in both
space groups. However, ligand electron density was significantly
better in the orthorhombic space group for both of these com-
plexes, and therefore all structures were refined in the ortho-
rhombic cell. Native crystals formed in a number of related space
groups in identical conditions, and determining the correct
space group was challenging for many crystals. The solved
structure reveals that WcbL adopts, as expected, the GHMP
sugar kinase fold (Figure 2A). A similar fold is seen in the structure
of a human N-acetylgalactosamine kinase (PDB: 2A2C; Fig-
ure 2B). The protein forms a head-to-tail dimer, with the two
active sites facing away from the dimer interface (Figure 2C), in
line with the native molecular weight predicted from size-exclu-
sion chromatography (Figure S1). A similar molecular arrange-
ment is seen in the structures of two putative sugar kinases
from Bacteroides thetaiotamicron and C. jejuni (PDB: 3K85 and
4N3O, respectively), which share 41% sequence identity with
WcbL.
Examination of the active site shows an enlarged binding
pocket, compared with the highest sequence identity homolog
with a solved structure (a galactokinase, PDB: 2DEI). Analysis
of these structures with CAVER v.3.0 (Chovancova et al.,
2012) showed a 27% increase in the pocket size, consistent
with the larger sugar substrate M7P. Comparison of the
sequence with galactokinases reveals a Q-L mutation at posi-
tion 162 (Figure S2). This facilitates the accommodation of thelogy 22, 1622–1632, December 17, 2015 ª2015 The Authors 1623
Figure 3. Interaction of WcbL with Substrates
(A) AMP-PNP binding to WcbL. Electron density map showing the binding of
AMP-PNP to WcbL with both molecules as sticks (left). The Mg2+ is shown in
green; co-ordination of the magnesium is shown in Figure S3. The 2Fo  Fc
electron density map (blue) was contoured at 1.06s for the AMP-PNP and the
neighboring residues; the positive and the negative 2Fo  Fc electron density
maps were both contoured at 3s. To the right is a schematic drawing of the
WcbL-AMP-PNP interactions.
(B) Binding of D-mannose to WcbL. Electron density map showing the binding
of the sugar to the protein; both molecules are shown as sticks. The 2Fo  Fc
electron density map (blue) was contoured at 1.3s for the D-mannose and the
neighboring residues; the positive and the negative 2Fo  Fc electron density
maps were both contoured at 3s (left); key interactions between WcbL and
D-mannose are shown on the right. The electron density map figures were
prepared with the PyMOL Molecular Graphics System (Schro¨dinger), and the
schemes of interactions betweenWcbL and the substrates were preparedwith
LigPlot+.
(C) Electrostatic surface representation of WcbL, showing AMP-PNP (yellow
and orange sticks) and D-mannose (green sticks) in the binding pocket (figure
produced using the UCSF Chimera package, Computer Graphics Laboratory,
University of California, San Francisco). WcbL, AMP-PNP, and D-mannose
interactions are shown on the right. WcbL is shown as a cyan cartoon, with
interacting side chains as sticks; AMP-PNP and D-mannose are shown as
sticks. AMP-PNP: carbon, violet; nitrogen, blue; oxygen, red; phosphorus,
orange; D-mannose carbon, yellow. WcbL: nitrogen, blue; oxygen, red.
Atoms involved in the catalytic reaction are indicated by black arrowheads;
key catalytic residues R13 and D163 are indicated by dashed arrows.
Figure produced using PyMOL.
Figure 2. Overview of WcbL Structure
(A) Monomeric crystal structure of WcbL in two orientations, showing the
GHMP kinase fold. The backbone is shown in cartoon representation, rainbow
colored from red (N terminus) to blue (C terminus).
(B) Superimposition of a representative sugar kinase onto the structure of
WcbL. The structures are shown as ribbons: WcbL, red; human N-acetylga-
lactosamine kinase (PDB: 2A2C), blue.
(C) Head-to-tail dimer of WcbL, with the two active sites facing away from the
dimer interface. The two domains of WcbL are colored cyan and magenta.
AMP-PNP and mannose are shown as spheres. Colors: nitrogen, blue; oxy-
gen, red; phosphorus, orange; AMP-PNP carbon, yellow; mannose carbon,
green.
Images (A) and (C) were prepared using the UCSF Chimera package from the
Computer Graphics Laboratory, University of California, San Francisco. (B)
was prepared with the PyMOL Molecular Graphics System (Schro¨dinger).extra carbon unit in the heptose sugar compared with the hex-
ose substrate of the related enzymes. Repeated attempts to
soak or co-crystallize the substrates M7P and ATP failed. How-
ever, soaking with the non-hydrolyzable substrate analog
AMP-PNP showed clear density for this nucleotide (Figure 3A).
Furthermore, soaking of native crystals with glycerol or
mannose showed that these two sugars both bind in the
sugar-phosphate binding pocket, where the sugar is expected
(Figure 3B; Figure S4). Superimposing the locations of AMP-
PNP and mannose shows that the location of these molecules
is compatible (Figure 3C). Indeed, the reactive atoms (O1 of
mannose, Pg of AMP-PNP) are located in positions compatible
with the expected reaction (nucleophilic attack of O1 on the
g-phosphate). This suggests that the locations of these two sub-
strate analogs in the structure are representative of the true
ligands. The ATP analog appears to form a network of interac-
tions with the enzyme, with the majority of interactions formed
with the phosphate, and the ribose O2 and O3 hydroxyls. The
phosphates interact with the side chains of R13 and D163, while1624 Chemistry & Biology 22, 1622–1632, December 17, 2015 ª2015the ribose ring interacts with the side chains of S118 and S119.
Interactions of the sugar substrate analog principally form with
the side chains of D22, Q162, and D163.The Authors
Figure 4. Kinase Activity and Cooperativity of WcbL
(A) Biophysical characterization of WcbL binding to ATP reveals an anti-
cooperative binding. The apparent dissociation constant KD is 33 ± 7 mM with
the cooperativity coefficient n = 0.6 ± 0.06, indicating a negative cooperativity
(open circles). The DSF experiment for M7P binding (closed circles) gives an
apparent dissociation constant KD for M7P of 968 ± 37 mM. All experiments
were performed in triplicate, and the data are representative of at least three
experiments. We separately showed that ATP shows negligible degradation at
58C during the relevant length of this experiment (not shown).
(B and C) WcbL kinase activity. For comparison, data were fitted to both the
Michaelis-Menten equation (red line) and an allosteric sigmoidal model (black
line).
(B) Wild-type WcbL activity is plotted as a function of ATP concentration,
keeping the concentration of M7P constant at 250 mM. An apparent kcat value
of 157 ± 5 min1 was calculated for wild-type. Calculated K1/2 value for ATP
was 240 ± 12 mM, whereas the Hill slope value h was 1.9 ± 0.1, suggesting
positive cooperativity.
(C) Allosteric behavior is observed for WcbL wild-type with the substrate M7P,
maintaining the concentration of ATP at 1 mM. Calculated K1/2 and kcat values
for the M7P substrate were 27 ± 1.6 mM and 182 ± 4 min1, respectively,
whereas the Hill coefficient was 1.5 ± 0.1.
(D)WcbL activity of wild-type andmutants. The kinetic assays were performed
using 6 mg/ml of WcbL wild-type and 60 mg/ml of mutants, keeping the con-
centrations of ATP and M7P constant at 1 mM and 0.5 mM, respectively. All
experiments were performed in triplicate, and the data are representative of at
least three experiments. Negative control represents the experiment carried
out without WcbL. Error bars represent SEM.
(E) In vivo validation of key ligand binding and catalytic residues. Western
hybridization using the capsule-specific monoclonal antibody 4VIH12 dem-
onstrates restoration of capsule production in B. pseudomallei K96243 DwcbL
when complementation is with unaltered wcbL. Complementation with wcbL
site-directed mutants fails to restore capsule production.
(F) Western hybridization using the O antigen-specific monoclonal antibody
CC6 demonstrates continued expression of native lipopolysaccharide in all
strains tested. No LPS is seen in the purified capsule control (10). In each
panel strains are spotted in the order: 1, B. pseudomallei K96243; 2,
B. pseudomallei K92643 DwcbL; 3, B. pseudomallei K92643 DwcbL (pBBR1-
MCS2); 4, B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL); 5,
B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL S118A/S119A/
S120A); 6, B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL R13A);
Chemistry & BioATP and M7P Binding Study by Differential Scanning
Fluorimetry
To further understand the activity of WcbL, we investigated its
binding to ATP using differential scanning fluorimetry (DSF) (Nie-
sen et al., 2007; Vivoli et al., 2014b). These data (Figure 4A)
showed an apparent negative cooperativity of binding: the
data suggested a dissociation constant K1/2 (the concentration
of substrate that produces a half-maximal enzyme velocity) of
33 ± 7 mM with the cooperativity coefficient n = 0.6 ± 0.06, indi-
cating an apparent negative cooperativity. As WcbL is dimeric,
this implies that the enzyme is perfectly anti-cooperative in its
binding to ATP. On the other hand, M7P did not show any coop-
erativity, and a dissociation constant of 968 ± 37 mM.
WcbL Activity and Kinetic Mechanism
WcbL activity was predicted due to its high sequence similarity
to HddA from Y. pseudotuberculosis (Cuccui et al., 2012; Paci-
nelli et al., 2002). This is thought to catalyze the phosphorylation
of D-a,b-D-heptose-7-phosphate to D-a-D-heptose-1,7PP
(M7PP) using ATP. To investigate the kinase function of WcbL,
we performed a discontinuous coupled assay, based on the
concerted action of WcbL and WcbN with detection of the
released inorganic phosphate. The kinetic data for ATP fitted
best to a cooperative model. K1/2 and kcat for ATP were deter-
mined as 240 ± 12 mM and 157 ± 5 min1, respectively, with a
Hill coefficient value h of 1.9 ± 0.1 (Figure 4B). Despite the nega-
tive cooperativity observed upon ATP binding in the DSF exper-
iment, the kinetic data suggested positive cooperativity. The
kinetic parameters for M7P also fitted best to a cooperative
model. The K1/2, kcat, and h values were determined to be 27 ±
1.6 mM, 182 ± 4 min1, and 1.5 ± 0.1, respectively (Figure 4C).
The structure of WcbL bound to AMP-PNP suggests that the
ATPmay bind in amanner that blocks access to the sugar-phos-
phate binding site. We therefore investigated the likely reaction
kinetics further by product inhibition experiments using ADP as
inhibitor. Addition of ADP caused changes in both KM and Vmax.
The kinetic data varying ATP concentrations shows a non-
competitive inhibitionwhich becomesuncompetitive at high con-
centrations of ADP (Ki = 411 ± 27 mM), whereas ADP inhibition at
different concentrations of M7P is non-competitive (Ki = 490 ±
41 mM; Figure S5). These results strongly suggest an ordered
sequential Bi-Bi mechanism of reaction. This is distinguished
from a random sequential Bi-Bi reaction (where ADP is expected
to act as a competitive inhibitor for ATP) and a ping-pong mech-
anism (where ADP is expected to be a competitive inhibitor of
M7P). The structural and kinetic data are therefore both consis-
tent with an ordered sequential Bi-Bi reaction mechanism
wherebyM7Pbinds toWcbLprior to ATP, andADP releases prior
to D-manno-a-D-heptose-1,7-bisphosphate.
Mutation of Key Ligand Binding and Catalytic Residues
Reveal a Likely Mechanism for Enzyme Activity
To better understand the action of the enzyme, we made mu-
tants in a range of likely substrate binding and catalytic residues.7, B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL D22A); 8,
B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL Q162L); 9,
B. pseudomallei K92643 DwcbL (pBBR1-MCS2-wcbL D163A); 10, purified
capsule from B. pseudomallei K96243.
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Figure 5. WcbL Shows Differential Cooperativity for ATP when
Mannose Bound
(A) Table indicating the hydrogen-bond energies where the hydrogen-bonding
network starts to collapse.
(B–D) Analysis of the hydrogen-bonding network of WcbL reveals an anti-
cooperative effect in the absence of the sugar substrate. The assessed
hydrogen-bonding network of WcbL is shown in the presence of one ATP
molecule (B), two ATPmolecules (C), and twomolecules each of mannose and
ATP (D). Hydrogen-bonding dilution was performed using Proflex (Jacobs
et al., 2001). Groups of residues in each structure that form part of a hydrogen-
bonding network that persists when hydrogen bonds weaker than 3.9 kcal/mol
(the point where the network ruptures in D) are removed are indicated by
different colors (colors match those in Figure S6). Bound ligands are shown as
all heavy atom representations (nitrogen, blue; oxygen, red; phosphorus, or-
ange; ATP carbon, yellow; mannose carbon, magenta). More detailed analysis
of the hydrogen-bonding network is shown in Figure S6.The residues chosen for mutation were residues involved in hep-
tose binding (Q162L and D22A), heptose/phosphate binding
(D163A), and ATP binding (R13A and S118A/S119A/S120A triple
mutant). All of these mutant proteins purified like the wild-type.
Every mutant led to a complete loss of catalytic activity (Fig-
ure 4D). In each case, the activity was below the limit of detection
of the assay, and at least 150 times less than the wild-type. To
further demonstrate the loss of function of these mutants, we
complemented the previously described B. pseudomallei wcbL
mutant (Cuccui et al., 2007) with either wild-type WcbL or with
one of the mutants. While wild-type enzyme successfully com-
plemented themutant and restored production of CPS-I (Figures
4E and 4F), none of themutants was able to restore any function.
These observations strongly support the notion that the interac-
tions with ATP and M7P predicted from the crystal structures
represent the biologically relevant binding of these substrates.
To further probe the mechanism, we performed an in silico ex-
amination of the normal modes and hydrogen-bonding networks1626 Chemistry & Biology 22, 1622–1632, December 17, 2015 ª2015of WcbL in the presence and absence of these ligands. These
analyses suggested that there was no significant alteration in
the major normal modes of the enzyme in the presence of any
combination of ligands. In contrast, analysis of the hydrogen-
bonding pattern displayed striking effects of ligand binding (Fig-
ures 5 and S6). The native state shows a structure with strong
stability: most of the structural elements are built from hydrogen
bonds of 4.1 kcal/mol or greater. The stability of the structure
is slightly enhanced when mannose is bound (0.3 kcal/mol),
or when one monomer binds to ATP (overall increase of
0.2 kcal/mol). In contrast, when the mannose-free protein binds
a second molecule of ATP, there is a loss of stability (0.5 kcal/
mol comparedwith one ATP bound; Figure 5C). In the case of the
mannose-bound WcbL, binding of a single ATP molecule results
in a large loss of stability, equivalent to having two ATP mole-
cules bound (Figure 5D). No further loss of stability is seen with
binding of a second ATP.
Drug-like Fragments Can Bind to and Inhibit WcbL
Asa first step toward producing novel interventions againstWcbL
and its homologs, we attempted to discover fragments that could
inhibit the enzyme. Assays were undertaken using our activity
assay, and DSF screening of WcbL. Analysis in duplicate of
more than 850 fragments showed that 29 fragments reproducibly
appeared as hits in both assays (Figure 6A). Following an initial re-
screening of 16 representative compounds (data not shown), we
selected the best inhibitor, 3-cyanochromone, for further study.
Four similar compounds are commercially available. Testing of
these showed that one neighbor, 6-bromo-3-cyanochromone,
has a similar activity, while the others (chromone, chromone-3-
carboxaldehyde, and 6,8-dichloro-3-cyanochromone) show
significantly weaker activity against WcbL (Figure 6B). We deter-
mined that the IC50 values for the twomostpotent inhibitors, 3-cy-
anochromoneand6-bromo-3-cyanochromone,were28±1.2mM
and 35 ± 1.1 mM, respectively (Figure 6C), while in a competitive
enzyme-inhibition model these showed inhibition constants Ki
of 10 ± 6 mM and 12 ± 5 mM (Figure 6D). These compounds
were delivering low micromolar affinities for the protein, despite
their low size, indicating that these are promising scaffolds for
newpharmaceuticals. The ligandefficiencyof 3-cyanochromone,
at more than 0.4 kJ/mol/atom, is very promising, and suggests
that these compounds have a good potential for further
development.
DISCUSSION
The B. pseudomallei CPS consists of a linear repeat of -3)-
2-O-acetyl-6-deoxy-b-D-manno-heptopyranose-(1-. The genes
required for the biosynthesis of this polysaccharide have been
mapped inB. pseudomallei (Reckseidler et al., 2001) andBurkhol-
deria mallei (DeShazer et al., 2001). wcbL is one of the genes
involved in the synthesis of the precursor sugar GDP-6-deoxy-
a-D-manno-heptopyranose (dDHep) from S7P, a pentose phos-
phate pathway intermediate (Cuccui et al., 2012). Analysis of the
homologous operon from Y. pseudotuberculosis (Pacinelli et al.,
2002) suggested that the WcbL homolog would act as a sugar
kinase, adding a phosphate to the 1-O position of D-a,b-D-hep-
tose-7-phosphate. Thishasbeenprovedcatalytically, as thecom-
plete enzymatic synthesis of GDP-6-deoxy-a-D-heptopyranoseThe Authors
Figure 6. Small Molecules Can Inhibit WcbL
(A) Analysis in duplicate of over 850 fragments from the Zenobia and May-
bridge fragment libraries showed reasonable reproducibility. 29 fragments
showed reproducible reduction of WcbL activity to less than 25% of control.
(B) Structure-activity relationship studies. Chromone derivatives were
screened against WcbL. The compounds were tested at final concentrations
of 10, 50, and 100 mM. The percentage of inhibition was calculated from the
equation (1  Vi/V0) 3 100, where Vi and V0 are the enzyme rates in the
presence and absence of inhibitors, respectively. The percentage of inhibition
was determined in triplicate.
(C) Dose-response curves for 3-cyanochromone (blue) and 6-bromo-3-cya-
nochromone (black) against WcbL. Assays were performed in triplicate using
the compounds in the concentration range 0–100 mM.
(D) Kinetic assay plots for the inhibitor 3-cyanochromone. The absorbance at
635 nm was plotted as a function of Log10[ATP]. The assay was performed in
triplicate using the following concentrations: 0 (filled circle), 10 (empty circle),
100 (empty triangle), or 500 mM (filled rhombus). The fitted data suggested a
competitive inhibition with an apparent inhibition constant Ki of 10 ± 6 mM.
Error bars represent SEM.from S7P has been reported (Butty et al., 2009). While two struc-
tures of other putative enzymes with the same predicted activity
as WcbL have been reported (PDB: 3K85 and 4N3O), neither of
these structures provided any insight into the binding of sub-
strates to the protein or the catalytic mechanism. WcbL repre-
sents an excellent target for novel antimicrobials: seven
membered sugars are rarely used in eukaryotes, and humans
have no equivalent to this pathway (Durka et al., 2011; Lee et al.,
2013; Taylor and Wright, 2008). Furthermore, kinases are among
the best validated drug targets, representing approximately one-
third ofprotein targetscurrently under investigation for drugdevel-Chemistry & Bioopment (Fabbro et al., 2012), while none of the other enzymes in
the pathway belong to classes that have previously had success-
ful drugs discovered. Ligand screening in the equivalent ADP-
linked sugar pathway found that the equivalent step to WcbL
was the easiest for discovering inhibitory compounds (De Leon
et al., 2006). A deeper understanding of the reaction, structure,
and interactions of this enzyme would therefore offer a strong
boost to attempts to develop novel antimicrobials targeting this
pathway.
The crystal structure of WcbL from B. pseudomallei reported
here shows that the enzyme indeed has the expected GHMP
sugar kinase fold (Figures 2A and 2B). The protein strongly re-
sembles the two orthologs solved by structural genomics con-
sortia. This gives us strong confidence that the structure and
conformation that we have identified represents the native struc-
ture of this enzyme.
We then solved the structure of WcbL co-crystallized with the
substrate analog AMP-PNP and soaked with D-mannose (Fig-
ure 3). These two analogs bind to the enzyme in the locations ex-
pected by analogy to previously determined complexes of sugar
kinases and their substrates. Notably, WcbL appears to bind to
the a-anomer of M7P. This anomer presents the 1-O atom of
M7P in a suitable conformation for reaction. This fits well with
our previously determined structure of GmhA, the previous
enzyme in the pathway (Harmer, 2010). In this structure, GmhA
appears to specifically catalyze the formation of the a-anomer
of M7P, supporting the conjecture that B. pseudomallei GmhA
catalyzes the closure of the sugar ring as well as isomerization
from the keto-to aldo sugar.
We then analyzed the interactions of WcbL and reactions of
WcbL. Analysis of reaction kinetics showed that WcbL is coop-
erative with respect to both M7P and ATP, with h values of 1.5
and 1.9, respectively (Figures 4B and 4C). As the predicted
ternary complex of WcbL, M7P, and ATP suggests that the bind-
ing of ATP blocks access to the binding site for M7P, we
analyzed the manner of the reaction. Using the product ADP to
determine the effects of product inhibition, we demonstrated
that this acts as an uncompetitive/non-competitive inhibitor (Fig-
ure S5). Were the reaction a random Bi-Bi reaction, or a ping-
pong reaction whereby M7P binds last, this would be expected
to be a competitive inhibitor (Cook and Cleland, 2007). This
therefore strongly suggests that the reaction is indeed an or-
dered sequential Bi-Bi reaction, where M7P binds first, then
ATP. Intriguingly, our biophysical analysis of the binding of
ATP to WcbL showed that ATP binding to WcbL is perfectly
anti-competitive (Figure 4A). This suggests that the interactions
of WcbL with its substrates are coordinated: in the absence of
M7P, binding of ATP is discouraged, as this blocks the M7P
binding site, while in the presence of the sugar-phosphate the
ATP binding and reaction are strongly cooperative.
We then used modeling approaches to further understand the
physical basis for these unusual cooperativity effects. We exam-
ined normal modes and hydrogen-bonding networks, as these
have previously explained functional effects in a number of sys-
tems (e.g. Wells et al., 2014). Surprisingly, the binding of ligands
to WcbL did not affect the normal modes preferred by the
enzyme. The most favored normal modes display considerable
movements in the enzyme, some of which involve the closing
of the active-site cleft between the two domains, and so are likelylogy 22, 1622–1632, December 17, 2015 ª2015 The Authors 1627
Figure 7. Proposed Mechanism of WcbL Activity
(A) D163 acts as a catalytic base, removing the proton from the M7P 1-O. The
1-O then attacks the ATP g-phosphate, forming a pentahedral intermediate
that is stabilized by magnesium, and the side chains of R13 and D163.
(B) Finally, this resolves to form the products, with D163 stabilizing the now
released b-phosphate of ADP.to be associated with catalysis. The requirement for flexibility for
catalysis perhaps explains why these features of the enzyme
are not affected by ligand binding. In contrast, analysis of the
hydrogen-bonding network showed considerable effects, local-
ized to the ligand binding regions. Strikingly, the binding of one
ATP in the absence of the sugar substrate leads to a tightening
of the hydrogen-bonding network and increased the stability of
the protomer binding ATP (Figure S6). Binding of a second
ATP, in contrast, requires a considerable loss of stability in the
protein (Figures 5B and 5C). This effect may explain the observa-
tion that ATP binding is strongly anti-cooperative in the absence
of the sugar substrate. Binding of the sugar causes a strong sta-
bilization effect. This stabilization is lost, and the hydrogen-
bonding network resembles the two-ATP bound state, when a
single ATP molecule binds. This suggests that, in the presence
of mannose, the binding of a first ATP requires the relaxation of
the hydrogen-bonding network, and no further penalty is
required to bind a second ATP. This appears to be consistent
with the positive cooperativity observed in the enzyme assays1628 Chemistry & Biology 22, 1622–1632, December 17, 2015 ª2015(Figures 5B–5D and S6). It therefore appears that the binding
of the sugar substrate triggers a switch in the hydrogen-bonding
network of the enzyme, so that ATP binding is favored and be-
comes cooperative, whereas in the absence of sugar, ATP bind-
ing at one site disfavors binding at the other site. Both the struc-
ture and catalytic properties of WcbL suggest that it obeys an
ordered sequential Bi-Bi mechanism whereby the sugar must
be loaded into the active site before ATP binding. It is therefore
essential for enzyme activity that the binding of ATP to both sites
is disfavored in the absence of the sugar substrate, while it will be
favorable in the presence of the sugar. The observed K1/2 values
for both ATP binding in the absence of sugar and for ATP con-
centration during catalysis are in the mid-micromolar range
and well below the usual cellular concentration of ATP. This
elegant mechanism of switching the cooperative behavior on
binding of the sugar substrate therefore provides the enzyme
with ATP interaction behavior appropriate for its mechanism
and cellular context.
We attempted to validate the complex and mechanism sug-
gested by the crystal structure.Wemademutants of several pro-
posed critical binding and active-site residues for both ATP and
M7P. All of these mutants purified well, but showed a complete
loss of activity in the enzymatic assay (at least 150-fold below the
wild-type; Figure 4D). To further validate this, we investigated the
capacity of these mutants to complement a knockout of WcbL in
B. pseudomallei. wcbl mutants of B. pseudomallei are unable to
produce CPS (Cuccui et al., 2007). Complementation with wild-
type WcbL showed a restoration of the capsule production
phenotype (Figures 4E and 4F). However, complementation
with WcbL with any of these mutations failed to restore any
CPS production.
Based on these observations, we propose a mechanism for
the activity of WcbL (Figure 7). We propose that D163 acts as
a catalytic base, removing the proton from the M7P 1-O. The
1-O then attacks the ATP g-phosphate, forming a pentahedral
intermediate that is stabilized bymagnesium and the side chains
of R13 and D163. Finally, this resolves to form the products, with
D163 stabilizing the now released b-phosphate of ADP. This
model is consistent with all of the structural and kinetic data.
Similar mechanisms have been observed with other sugar ki-
nases (Huang et al., 2013; Megarity et al., 2011).
Finally, we used our knowledge of the reactions and structure
of WcbL to search for potential inhibitors. Kinases have been
shown to be excellent targets for fragment screening, as they
often provide very avid binders. A screen of more than 850
compounds by DSF and enzyme assays highlighted a range of
potential inhibitors that showed activity at millimolar concentra-
tions. Further testing of these showed that one, 3-cyanochro-
mone, inhibitedWcbL at lowmicromolar concentrations (Figures
6C and 6D). Testing of commercially available analogs of this
compound showed that the cyano group is highly important to
the interaction, as chromone-3-carboxaldehyde showed a
much weaker IC50 than the cyano equivalent, while chromone it-
self does not inhibit WcbL. The 8-bromo equivalent of 3-cyano-
chromone showed IC50 and Ki a very similar to those of the orig-
inal compound, indicating that the 8-position is suitable for
modification, while the 6,8-dichloro equivalent is a far less potent
inhibitor, indicating that the 6-position of the chromone ring is
not suitable for modification (Figure 6B). These observationsThe Authors
indicate that there is a good potential for developing specific in-
hibitors for WcbL: a very moderate screen has identified a mole-
cule with good potency, and a very high ligand efficiency of more
than 0.4 kJ/mol/heavy atom. With a more extensive screening, it
is likely that a very potent inhibitor of WcbL could be identified.
This would be a very attractive proposition, offering the potential
to deliver a compound that could render pathogenic micro-
organisms non-infective with minimal damage to commensal
organisms.
Our study reveals the elegant regulation of ATP binding that
WcbL uses to tune its ligand occupation. The exquisite arrange-
ment of the hydrogen-bonding network allows WcbL to operate
a sequentially ordered Bi-Bi kinetic mechanism, with positive
cooperativity with respect to both substrates. The structure of
WcbL reveals a deep binding pocket for the substrate M7P,
with specific changes to the structure to accommodate a hep-
tose rather than a hexose sugar. Based on the structural and ki-
netic data presented herein, we have proposed amechanism for
the action of WcbL, and show that small drug-like fragments are
competent in binding to the active site and inhibiting WcbL in
competition with ATP. Given that WcbL knockouts present a
very strong phenotype, these data strongly suggest that WcbL
would be an excellent target for adjunct therapies to prevent
the formation of protective surface polysaccharides in Gram-
negative bacteria.
SIGNIFICANCE
This study reports the structure and functional characteriza-
tion of WcbL. This enzyme is critical in capsular polysaccha-
ride biosynthesis in the human pathogen Burkholderia
pseudomallei. Our most significant finding is that this
enzyme regulates substrate binding order through the
global protein structure. This concept has potential implica-
tions for bisubstrate enzymes: these constitute around 60%
of all enzymes, and most of these require a defined binding
order. We further elucidate a likely enzyme activity mecha-
nism, validated both in vitro and in vivo. Finally, we demon-
strate that small molecules can inhibit WcbL with high affin-
ity, and show at least one scaffold that can act as a potential
lead compound. Our observations validate this enzyme as
an excellent target for antimicrobial development.
EXPERIMENTAL PROCEDURES
Construct Cloning
Full-length wcbL from B. pseudomallei strain K96423 (gift of Rick Titball,
University of Exeter) was cloned into the pNIC28-Bsa4 expression vector using
ligation-independent cloning (Savitsky et al., 2010).
The wcbL-pNIC28 construct was used for site-directed mutagenesis
using the QuikChange Lightning II site-directed mutagenesis kit (Agilent).
Primers (Life Technologies) were designed using the primer design tool
available at http://www.genomics.agilent.com/primerDesignProgram.jsp. All
mutants were verified by sequencing.
Constructs for expression in B. pseudomallei were prepared by PCR ampli-
fying thewild-type and site-directedmutants ofwcbLwith extensions that pro-
vided a ribosome binding site for Burkholderia, and sequence synonymous
with the multiple cloning site of pBBR1-MCS2 (Kovach et al., 1995). The
pBBR1-MCS2 plasmid was also amplified by PCR. Both PCR products were
treated with DpnI (Fermentas) to eliminate remaining original plasmid. The
PCR products were gel purified, and the concentration determined using aChemistry & BioNanodrop ND2000c spectrophotometer. Plasmid and insert were mixed
in a 1:3 M ratio, and cloned using the Gibson cloning kit (NEB) using the
manufacturer’s recommendations. All successful constructs were verified by
sequencing.
Expression and Purification
Constructs were transformed into Rosetta (DE3) cells (Merck) and grown in
ZYM-5052 media (Studier, 2005) supplemented with 100 mg/ml kanamycin
and 20 mg/ml chloramphenicol. Cells were grown at 37C until OD600 was
0.6 and then at 20C. Bacteria were harvested after 20 hr, and suspended in
20 mM Tris-HCl (pH 8.0) and 0.5 M NaCl (buffer A). The cells were lysed using
a Soniprep 150 sonicator (MSE). The lysate was clarified by centrifuging at
20,000 3 g for 30 min. The supernatant was loaded over a HisTrap Crude
FF column (1 ml) on an A¨KTAxpress chromatography system (GE Healthcare),
or to nickel-Sepharose beads (1 ml; GE Healthcare) in a gravity flow column.
The column was washed with buffer A supplemented with 25 mM imidazole-
HCl (pH 8.0), and the protein eluted with buffer A supplemented with
250 mM imidazole-HCl (pH 8.0). The peak was loaded onto a Superdex 200
16/60-hr size-exclusion column (GE Healthcare) and eluted isocratically into
10 mM HEPES (pH 7.0), 0.5 M NaCl, and 5 mM citrate (pH 6.5). An E179A/
E180A/E181A triple mutant protein was purified as above but without addition
of citrate at the size-exclusion step. Selenomethionine-labeledWcbL was pre-
pared using PASM-5052 media (Studier, 2005), and purified as above. GmhA
and WcbN were prepared as described by Harmer (2010).
Crystallization and Structure Determination
WcbL proved to crystallize spontaneously at concentrations exceeding
5 mg/ml at 4C in the buffer used for size-exclusion chromatography. Crystal-
lization was controlled by concentrating samples freshly each day from a stock
at approximately 1mg/ml, and by incubating drops of 1–4 ml under oil in micro-
batch plates (Douglas Instruments). The E179A/E180A/E181A triple mutant
crystallized spontaneously, and in a more reproducible manner, at concentra-
tions of around 3 mg/ml. Soaking was attempted by adding substances
dissolved in cryoprotectant (see Table S1) to protein at concentrations of
1–25 mM, and incubating at 4C for up to 90 min. Co-crystallization was
performed by adding compounds to WcbL E179A/E180A/E181A pre-concen-
trated to approximately 3mg/ml, and adding partner molecules to the concen-
trations required. Co-crystals formed naturally at 4C under oil. Either glycerol
or mixture 5 from the CryoProtX kit (Molecular Dimensions) was used as a
cryoprotectant. Soaking with mannose was achieved by utilizing 30% (w/v)
D-mannose as a cryoprotectant.
Data were collected on beamlines I03 and I04-1 at the Diamond Synchrotron
light source (Didcot, UK) at 100 K in a stream of gaseous nitrogen using ADSC
(for glycerol complex and selenomethionine data) or Pilatus detectors. Data
were processed and scaled using XDS (Kabsch, 2010) and AIMLESS (Evans
and Murshudov, 2013) in the Xia2 (Winter et al., 2013) pipeline. Further
data and model manipulation was carried out using PHENIX (Adams et al.,
2010) and the CCP4 suite of programs (Winn et al., 2011).
While several wavelengths were collected from a single crystal of selenome-
thionine protein, the WcbL structure was solved by SAD in the SHELXC/D/E
pipeline (Sheldrick, 2010) implemented in HKL2MAP (Pape and Schneider,
2004) using the selenomethionine high-energy remote data and glycerol com-
plex as native. For the correct hand, the correlation for the partial structure
against the native data was 54.45%. The full atomic model was built using
ARP/wARP (Langer et al., 2013; Murshudov et al., 2011). Poorly defined loops
were rebuilt with the help of BUSTER (Bricogne et al., 2011). Model rebuilding
was done in Coot (Emsley et al., 2010). The dictionary definitions for the ligands
were created using JLIGAND (Lebedev et al., 2012).
Differential Scanning Fluorimetry
DFS was performed using a StepOne qPCR machine (Applied Biosystems). In
brief, purified WcbL was diluted to 0.1 mg/ml in 10 mM HEPES (pH 7.0),
150 mM NaCl, and 83 SYPRO Orange dye (Invitrogen; Niesen et al., 2007),
in a final volume of 20 ml. ATP was added to a final concentration between
0.1 mM and 5 mM. All samples were prepared in triplicate. To generate the
melting curve, the samples where heated in a gradient from 25 to 99C
over 50 min and the fluorescence measured every 0.4C. The melting temper-
ature was determined from the peaks of the first derivatives of the meltinglogy 22, 1622–1632, December 17, 2015 ª2015 The Authors 1629
curve using Protein Thermal Shift software version 1.0 (Applied Biosystems),
and plots were produced using the programGraphPad Prism 6.0.2. The disso-













where KD is the dissociation constant, in the same units that were used for the
ligand concentrations; Top and Bottom are the melting temperatures at infinite
ligand concentration and no ligand concentration, respectively, and n repre-
sents the Hill coefficient describing cooperativity (Vivoli et al., 2014b).
Kinetic Assays
WcbL activity was measured using a discontinuous coupled system with
WcbN, using ATP and D-manno-a,b-D-heptose-7-phosphate (M7P) as sub-
strates. The activity was measured with the Pi Colorlock Gold colorimetric
assay kit (Innova Biosciences). Reactions were performed in 100 ml, and con-
sisted of 10 mM HEPES (pH 8.0), 10 mM CaCl2, 10 mMMgCl2, 6 mg/ml WcbL,
80 mg/ml WcbN, 1 mM ATP and 0–500 mMM7P, or 250 mMM7P and 0–1 mM
ATP. WcbL mutants were used at a final concentration of 60 mg/ml. Assays
were performed in triplicate, at 37C for 10 min, followed by incubation for
10 min at 70C to stop the reaction. Pi Colorlock Gold mix (17 ml) was added
to the assay mixture (68 ml) and incubated for 5 min on ice. Stabilization buffer
(6.8 ml) was added, the reaction mix incubated for 10 min at room temperature,
and the absorbance at 635 nm measured using a Tecan Infinite M200
microplate reader. Rates were calculated using a standard curve of phos-
phate. Reactions in which ATP, M7P, or recombinant WcbL were omitted
served as controls. The data were fitted using Michaelis-Menten and cooper-
ative sigmoidal equations to extrapolate K1/2 and Vmax using GraphPad Prism
version 6.0.2.
Medium Throughput Screening for WcbL Inhibitors
Compound Sources
Compounds were taken from the Zenobia fragment library 1 (Zenobia Frag-
ment Libraries, 352 compounds), and from theMaybridge Ro3 fragment library
1 (Thermo Fisher, 500 compounds). The Zenobia library was prepared in
DMSO, and a working stock at 50 mM prepared; the Maybridge library was
prepared in DMSO, and a working stock at 25 mM prepared (both according
to the manufacturer’s recommendations).
Enzymatic Assay
An enzymatic assay of WcbL was performed in a manner similar to that
described above. GmhA was used to convert the commercially available sub-
strate sedoheptulose-7-phosphate (S7P) intoM7P. Reactions were performed
in 100 ml, and consisted of 10 mM HEPES (pH 8.0), 10 mM CaCl2, 10 mM
MgCl2, 52.5 mg/ml GmhA, 6 mg/ml WcbL, 34 mg/ml WcbN, 200 mM ATP, and
500 mM S7P. Inhibitors were added to a total of 4% of the reaction volume
(2mM for Zenobia library, 1mM forMaybridge library). Controls were prepared
with 4% DMSO. Assays were performed in 96-well plates, with each plate
containing four positive control wells and four negative control plates (lacking
WcbL). Reactions were performed as described above, and analyzed using
the Pi Colorlock Gold detection reagent. All experiments were performed
in duplicate, and compounds considered as hits if they reduced the rate of
reaction to less than 25% in both replicates.
DSF Binding Assay
DSF assays were set up in 96-well white qPCR plates (Fisher) and sealed
with optical tape (Bio-Rad). Samples contained 1 mM WcbL, 10 mM HEPES
(pH 7.0), 150 mM NaCl, and 53 SYPRO Orange in a final reaction volume of
40 ml. Compounds were added to 10% of the working concentration
(2.5mM forMaybridge library and 5mM for Zenobia library). TheDSF reactions
were performed using an Mx3000 qPCR machine (Agilent; experimental
parameters: 25C for 5 min, then 1C rise per minute to 95C). Data were
analyzed using the methods of Niesen et al. (2007). Tm values were calculated
by non-linear regression, fitting the Boltzmann equation to the melting curves
using GraphPad Prism version 5. All experiments were performed in duplicate.
Compounds were considered as hits if both samples gave melting tempera-
tures raised above 42C (88th percentile of all samples tested; WcbL treated
with DMSO alone gave a melting temperature of 37C ± 1C).1630 Chemistry & Biology 22, 1622–1632, December 17, 2015 ª2015Compound Selection, Structure-Activity Relationship Studies, and
Determination of IC50 and Ki Values for the Best Inhibitors
General Assay Conditions
Compounds at appropriate concentrations (see below) were placed into plates
containing WcbL (6 mg/ml), GmhA (60 mg/ml) and WcbN (80 mg/ml). After a
30-min preincubation at room temperature, S7P (final concentration 500 mM)
and ATP (final concentration 1 mM) were added, and residual enzyme activity
was monitored using the Pi Colorlock reagent as described above.
Compound Selection
Compounds that were considered ‘‘hits’’ in both of the initial screens were
selected for more detailed studies. Fresh samples of each compound were
obtained, and the compounds retested using concentrations of compound
between 20 mM and 5 mM.
Structure-Activity Relationship Study
Compounds were added at concentrations of 10, 50, and 100 mM. The per-
centage of inhibition was calculated from the equation (1 Vi/Vo)3 100, where
Vi and Vo are the enzyme rates in the presence and in the absence of inhibitors,
respectively. Each point was determined in triplicate.
Dose-Response Experiments
Compounds 3-cyanochromone and 6-bromo-3-cyanochromone were added
at serial dilutions to give final concentrations between 1 and 100 mM. The
data obtained were fitted using GraphPad Prism version 6.0.2, applying the




1+ 10ðlog10 IC50log10 ½IÞh
; (Equation 2)
where the Response decreases as [I] (inhibitor concentration) increases; Top
and Bottom are the plateaus in same units as Response; Log10IC50 is in the
same log units as [I]; and h is the slope factor, unitless.
Ki determination
To determine the inhibition constant for 3-cyanochromone, compound was
used at 0, 10, 100, and 500 mM as described above. The ATP concentration
used in the reaction was varied from 0 to 1 mM, and enzyme activity was
detected as described above. The Ki value was calculated using the equation
for competitive inhibition:









where Vmax is the maximum enzyme velocity; [S] is the substrate concentra-
tion; KM is the Michaelis constant (same units as [I]); [I] is the inhibitor concen-
tration; and Ki is the inhibition constant.
The Ki for 6-bromo-3-cyanochromone was extrapolated using the following







Kinetic studies of the reactionmechanism ofWcbLwere performed by product
inhibition experiments using the assay methodology outlined above. For these
experiments, ADP was used as the product inhibitor. In brief, ADP at concen-
trations of 100, 500, and 1,000 mMwas placed into plates containing 12 mg/ml
WcbL, 80 mg/ml WcbN, 1 mM ATP and 0–250 mM M7P, or 250 mM M7P and
0–1 mM ATP, and residual enzyme activity monitored using the Pi Colorlock
reagent as described above. The initial rates derived from these inhibition
experiments were fitted to equations representative of competitive, non-
competitive, mixed, or uncompetitive inhibition by a non-linear least-squares
approach using GraphPad Prism version 6.0.2. The best fits of the data
were compared using a combination of visual inspection, comparison of R2
value, and Akaike’s Information Criteria.
In Vivo Assays
Complementation of the previously described B. pseudomallei wcbL mutant
(Cuccui et al., 2007) was completed using tri-parental mating. In brief,
pBBR1-MCS2 complementation vectors (see above) were transformed intoThe Authors
Escherichia coli JM109 and selected using 50 mg/ml kanamycin. A 10 ml
aliquot from an overnight culture of a given donor strain, the B. pseudomallei
K96243 DwcbL recipient strain, and the E. coli HB101 (pRK2013) helper strain
were inoculated as overlapping spots onto a nitrocellulose membrane previ-
ously placed on the surface of an L-agar plate. After an overnight incubation
at 37C, the bacterial growth was harvested into PBS (1 ml) and aliquots
spread onto L-agar containing 50 mg/ml gentamicin and 750 mg/ml kanamycin.
The phenotype of the complemented strains was assessed using dot-blot
western hybridization. In brief, the complemented B. pseudomallei DwcbL iso-
lates were incubated in L-broth containing 750 mg/ml kanamycin overnight at
37C. Cells were pelleted, suspended in PBS, and inactivated by heating to
80C for 4 hr. Once cooled, aliquots of each isolate (10 ml) were dried onto a
nitrocellulose membrane and the membranes used for western hybridization
as previously described (Nelson et al., 2004), using the mouse-derived
capsule-specific monoclonal antibody 4VIH12 and O antigen specific mono-
clonal antibody CC6 (Ellis, 2000) for detection. SigmaFast DAB (Sigma) was
used for development of the membranes.
Computational Studies
Samples were prepared for computational analysis by setting all residues with
alternative conformations to the most favored conformation using PHENIX. A
structure with one AMP-PNP was prepared by removing the AMP-PNP from
molecule B, and altering the ions to those present in the native structure. Struc-
tures with mannose and one (in molecule B) or two AMP-PMPmolecules were
prepared by adding the AMP-PNP molecules and ions from each molecule to
the relevant molecule in themannose complex. Explicit hydrogens were added
to the structure, and the structure was optimized using the online version of
YASARA (Krieger et al., 2009). Normal mode analysis was undertaken using
the elNe´mo server (http://www.sciences.univ-nantes.fr/elnemo/) (Suhre and
Sanejouand, 2004), using standard settings. Hydrogen-bonding network anal-
ysis was performed using Proflex (Jacobs et al., 2001). Hydrogen-bond dilu-
tion was performed using default settings.
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